{"DataElement":{"publicId":"11518163","version":"1","preferredName":"Therapeutic Procedure Veno-Occlusive Disease And/Or Sinusoidal Obstruction Syndrome Administered Therapy Administered Type","preferredDefinition":"A description of the veno-occlusive disease and/or sinusoidal obstruction syndrome therapy that was administered.","longName":"VOD_SOS_THRY_ADMIN_TP","context":"COG","contextVersion":"1","DataElementConcept":{"publicId":"11518162","version":"1","preferredName":"Therapeutic Procedure Veno-Occlusive Disease And/Or Sinusoidal Obstruction Syndrome Administered","preferredDefinition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.:Disorder in which veins are partially or completely obstructed or the blood flow through the veins is suboptimal.--2004_Used to indicate that either or both of two items or options may be valid._A disorder characterized by inflammation and damage of the hepatic sinusoidal endothelial cells of the hepatic venules that leads to venular occlusion and hepatocellular necrosis. It is most often a conditioning-related toxicity that results as a complication of hematopoietic stem cell transplantation (HSCT). It has also been described in populations of individuals who have ingested pyrrolizidine plant alkaloids. The clinical signs and symptoms include hyperbilirubinemia, hepatomegaly, and fluid retention._The act of having given something (e.g., a medication or test).","longName":"2512834v1.00:11518161v1.00","context":"COG","contextVersion":"1","ObjectClass":{"publicId":"2512834","version":"1","preferredName":"Therapeutic Procedure","preferredDefinition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","longName":"C49236","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B89860A-B9D6-3798-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-08-21","endDate":null,"createdBy":"UMLLOADER_AGNIS","dateCreated":"2006-08-21","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"11518161","version":"1","preferredName":"Veno-Occlusive Disease And/Or Sinusoidal Obstruction Syndrome Administered","preferredDefinition":"Disorder in which veins are partially or completely obstructed or the blood flow through the veins is suboptimal.--2004_Used to indicate that either or both of two items or options may be valid._A disorder characterized by inflammation and damage of the hepatic sinusoidal endothelial cells of the hepatic venules that leads to venular occlusion and hepatocellular necrosis. It is most often a conditioning-related toxicity that results as a complication of hematopoietic stem cell transplantation (HSCT). It has also been described in populations of individuals who have ingested pyrrolizidine plant alkaloids. The clinical signs and symptoms include hyperbilirubinemia, hepatomegaly, and fluid retention._The act of having given something (e.g., a medication or test).","longName":"C8301:C48928:C26793:C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Veno-Occlusive Disease","conceptCode":"C8301","definition":"Disorder in which veins are partially or completely obstructed or the blood flow through the veins is suboptimal.--2004","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"And/Or","conceptCode":"C48928","definition":"Used to indicate that either or both of two items or options may be valid.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Sinusoidal Obstruction Syndrome","conceptCode":"C26793","definition":"A disorder characterized by inflammation and damage of the hepatic sinusoidal endothelial cells of the hepatic venules that leads to venular occlusion and hepatocellular necrosis. It is most often a conditioning-related toxicity that results as a complication of hematopoietic stem cell transplantation (HSCT). It has also been described in populations of individuals who have ingested pyrrolizidine plant alkaloids. The clinical signs and symptoms include hyperbilirubinemia, hepatomegaly, and fluid retention.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EC6C3F56-2A9F-3621-E053-731AD00A3683","latestVersionIndicator":"Yes","beginDate":"2022-11-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-11-01","modifiedBy":"KUMMEROA","dateModified":"2022-11-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EC6C3F56-2AA0-3621-E053-731AD00A3683","latestVersionIndicator":"Yes","beginDate":"2022-11-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-11-01","modifiedBy":"KUMMEROA","dateModified":"2022-11-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"5577902","version":"1.1","preferredName":"Therapy Administered Type","preferredDefinition":"the type of therapy being administered.","longName":"5577902v1.10","context":"COG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"5170771","version":"1","preferredName":"Other","longName":"5170771","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2E4D2332-841D-A760-E050-BB89AD43734F","latestVersionIndicator":"Yes","beginDate":"2016-03-18","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-03-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EC6CA9E9-8004-49CA-E053-731AD00AF12E","beginDate":"2016-11-16","endDate":null,"createdBy":"DAVISJ","dateCreated":"2022-11-01","modifiedBy":"ONEDATA","dateModified":"2022-11-01","deletedIndicator":"No"},{"value":"Defibrotide","valueDescription":"Defibrotide","ValueMeaning":{"publicId":"5127452","version":"1","preferredName":"Defibrotide","longName":"5127452","preferredDefinition":"A polydeoxyribonucleotide with antithrombotic, thrombolytic, and fibrinolytic properties.  Defibrotide induces the release of prostaglandin 12 and reduces the expression of adhesion molecules on endothelial cells, thereby interfering with platelet and leukocyte adhesion to the endothelium. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Defibrotide Sodium","conceptCode":"C1064","definition":"A polydeoxyribonucleotide with antithrombotic, thrombolytic, and fibrinolytic properties.  Defibrotide induces the release of prostaglandin 12 and reduces the expression of adhesion molecules on endothelial cells, thereby interfering with platelet and leukocyte adhesion to the endothelium. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C5DDD88-FBF7-F93D-E050-BB89AD437D4E","latestVersionIndicator":"Yes","beginDate":"2016-02-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EC6CA9E9-8005-49CA-E053-731AD00AF12E","beginDate":"2016-11-16","endDate":null,"createdBy":"DAVISJ","dateCreated":"2022-11-01","modifiedBy":"ONEDATA","dateModified":"2022-11-01","deletedIndicator":"No"},{"value":"Diuretic","valueDescription":"Diuretic","ValueMeaning":{"publicId":"6422927","version":"1","preferredName":"Diuretic","longName":"6422927","preferredDefinition":"A class of agents that increases the production of urine by the kidney. Via various mechanism of actions, diuretics retain water in urine, thus provides a means of forced diuresis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diuretic","conceptCode":"C448","definition":"A class of agents that increases the production of urine by the kidney. Via various mechanism of actions, diuretics retain water in urine, thus provides a means of forced diuresis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"74AAE53F-EF02-6E81-E053-F662850A3492","latestVersionIndicator":"Yes","beginDate":"2018-08-30","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2018-08-30","modifiedBy":"ONEDATA","dateModified":"2018-08-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EC6CA9E9-8007-49CA-E053-731AD00AF12E","beginDate":"2018-08-30","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2022-11-01","modifiedBy":"ONEDATA","dateModified":"2022-11-01","deletedIndicator":"No"},{"value":"Corticosteroid","valueDescription":"Corticosteroid","ValueMeaning":{"publicId":"3951357","version":"1","preferredName":"Corticosteroid","longName":"3951357","preferredDefinition":"Hormones synthesized in the cortex of the adrenal gland and consist of two subclasses, glucocorticoids (carbohydrate regulation) and mineralocorticoids (electrolyte regulation).(NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Corticosteroid","conceptCode":"C2322","definition":"Hormones synthesized in the cortex of the adrenal gland and consist of two subclasses, glucocorticoids (carbohydrate regulation) and mineralocorticoids (electrolyte regulation).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EAE91AA1-BCFE-7D56-E040-BB89AD4361DC","latestVersionIndicator":"Yes","beginDate":"2013-11-11","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-11-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EC6CA9E9-8008-49CA-E053-731AD00AF12E","beginDate":"2018-08-30","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2022-11-01","modifiedBy":"ONEDATA","dateModified":"2022-11-01","deletedIndicator":"No"},{"value":"Ursodeoxycholic acid","valueDescription":"Ursodiol","ValueMeaning":{"publicId":"3380290","version":"1","preferredName":"Ursodiol","longName":"3380290","preferredDefinition":"A synthetically-derived form of ursodiol, a bile acid produced by the liver and secreted and stored in the gallbladder.  Also produced by the Chinese black bear liver, ursodiol has been used in the treatment of liver disease for centuries.  This agent dissolves or prevents cholesterol gallstones by blocking hepatic cholesterol production and decreasing bile cholesterol.  Ursodiol also reduces the absorption of cholesterol from the intestinal tract.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ursodiol","conceptCode":"C1818","definition":"A synthetically-derived form of ursodiol, a bile acid produced by the liver and secreted and stored in the gallbladder.  Also produced by the Chinese black bear liver, ursodiol has been used in the treatment of liver disease for centuries.  This agent dissolves or prevents cholesterol gallstones by blocking hepatic cholesterol production and decreasing bile cholesterol.  Ursodiol also reduces the absorption of cholesterol from the intestinal tract.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97CA559-A4DB-BAA9-E040-BB89AD430252","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EC6CA9E9-8009-49CA-E053-731AD00AF12E","beginDate":"2019-05-23","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2022-11-01","modifiedBy":"ONEDATA","dateModified":"2022-11-01","deletedIndicator":"No"},{"value":"Other prophylaxis","valueDescription":"Other prophylaxis","ValueMeaning":{"publicId":"6831631","version":"1","preferredName":"Other prophylaxis","longName":"6831631v1.00","preferredDefinition":"Different than the one(s) previously specified or mentioned._Therapeutic, nutritional, environmental, social and/or behavioral interventions at the societal, community, organizational or individual levels to reduce, modify or stop the course of a disease.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Preventive Intervention","conceptCode":"C15843","definition":"Therapeutic, nutritional, environmental, social and/or behavioral interventions at the societal, community, organizational or individual levels to reduce, modify or stop the course of a disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E87E8D5-6D31-33F9-E053-F662850A7F8C","latestVersionIndicator":"Yes","beginDate":"2019-07-25","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-07-25","modifiedBy":"KUMMEROA","dateModified":"2022-11-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EC6CA9E9-800A-49CA-E053-731AD00AF12E","beginDate":"2019-07-25","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2022-11-01","modifiedBy":"ONEDATA","dateModified":"2022-11-01","deletedIndicator":"No"},{"value":"Milk Thistle","valueDescription":"Milk Thistle","ValueMeaning":{"publicId":"2578295","version":"1","preferredName":"Milk Thistle","longName":"2578295","preferredDefinition":"A substance derived from any of several Old World coarse prickly-leaved shrubs and subshrubs including the plant Silybum marianum.  Milk thistle's active chemical component is silymarin, which is a combination of flavonoids such as silibinin, dehydrosilibinin, silychristin and silydianin.  These compounds are antioxidants and may alter the membrane structure of the liver cell, thereby blocking the absorption of toxins; they may also stimulate the production of new liver cells. In addition, milk thistle may increase cellular adenosine triphosphate (ATP) levels, exhibiting dose-dependent cardiac myocyte cytoprotection against doxorubicin.  The silibinin component of milk thistle has been shown to inhibit growth factor receptor-mediated mitogenic and cell survival signaling, thereby inhibiting tumor growth. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Milk Thistle","conceptCode":"C29261","definition":"A substance derived from any of several Old World coarse prickly-leaved shrubs and subshrubs including the plant Silybum marianum.  Milk thistle's active chemical component is silymarin, which is a combination of flavonoids such as silibinin, dehydrosilibinin, silychristin and silydianin.  These compounds are antioxidants and may alter the membrane structure of the liver cell, thereby blocking the absorption of toxins; they may also stimulate the production of new liver cells. In addition, milk thistle may increase cellular adenosine triphosphate (ATP) levels, exhibiting dose-dependent cardiac myocyte cytoprotection against doxorubicin.  The silibinin component of milk thistle has been shown to inhibit growth factor receptor-mediated mitogenic and cell survival signaling, thereby inhibiting tumor growth. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEE4-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-15","modifiedBy":"ONEDATA","dateModified":"2006-03-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EC6CA9E9-800B-49CA-E053-731AD00AF12E","beginDate":"2019-07-25","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2022-11-01","modifiedBy":"ONEDATA","dateModified":"2022-11-01","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"EC6CA9ED-F9CE-49C6-E053-731AD00A860C","latestVersionIndicator":"Yes","beginDate":"2016-11-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-11-01","modifiedBy":"KUMMEROA","dateModified":"2022-11-01","changeDescription":"Workflow and Registration Status Changed per Brenda Duggan; 05.16.18","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"PQT","type":"Preferred Question Text","description":"What was the veno-occlusive disease and/or sinusoidal obstruction syndrome therapy administered?","url":null,"context":"COG"},{"name":"COG CRF Text 1","type":"Alternate Question Text","description":"SOS/VOD treatment:","url":null,"context":"COG"},{"name":"COG CRF Text 2","type":"Alternate Question Text","description":"SOS treatment agents administered:","url":null,"context":"COG"},{"name":"COG CRF Text 3","type":"Alternate Question Text","description":"SOS treatment:","url":null,"context":"COG"},{"name":"COG CRF Text 4","type":"Alternate Question Text","description":"SOS treatment during this reporting period:","url":null,"context":"COG"}],"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"EC6C7170-9085-4337-E053-731AD00A803D","latestVersionIndicator":"Yes","beginDate":"2022-11-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-11-01","modifiedBy":"KUMMEROA","dateModified":"2022-11-01","changeDescription":null,"administrativeNotes":"2022.11.1 Created to replace CDE 5577930. ak","unresolvedIssues":null,"deletedIndicator":"No"}}